Please make JavaScript on and see this site.
Our recommended contents
FY 2018 (No.352-)
1. Trastuzumab (genetical recombination) and other follow-on biologics 2. Nivolumab (genetical recombination) 3. Palbociclib 4. Pembrolizumab (genetical recombination)
Eliglustat tartrate (and 5 others)
1. Nusinersen sodium 2. Axitinib
1. (1) Aluminum potassium sulfate hydrate/tannic acid (with saline) (2) Aluminum potassium sulfate hydrate/tannic acid (with analgesic agents) 2. Calcitriol (injectable dosage form) 3. Freeze-dried live attenuated varicella vaccine
1. Secukinumab (genetical recombination) 2. Lamotrigine 3. Lenvatinib mesilate
(1) Atorvastatin calcium hydrate (2) Ezetimibe/atorvastatin calcium hydrate (3) Pravastatin sodium (4) Amlodipine basilate/atorvastatin calcium hydrate (and 11 others)
1. Ceftriaxone sodium hydrate
(1) Apremilast (and 1 other)
Revision of the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP Ordinance)
1. Pegfilgrastim (genetical recombination) 2. Filgrastim (genetical recombination, follow on biologics) 3. Lenograstim (genetical recombination)
1. Pembrolizumab (genetical recombination)
(1) Omarigliptin (2) Saxagliptin hydrate (3) Trelagliptin succinate (and 3 others)
(1) Tolvaptan (2) Anagliptin, linagliptin, teneligliptin hydrobromide hydrate, teneligliptin hydrobromide hydrate/canagliflozin hydrate (3) Anagliptin (4) Sterile talc
Tolvaptan (and 5 others)
Copyright (C) Pharmaceuticals and Medical Devices Agency, All Rights Reserved.